{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:48:17Z","timestamp":1776235697460,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Danish Research Foundation"},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["101071485"],"award-info":[{"award-number":["101071485"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92726-x","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:23:29Z","timestamp":1744176209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A fragment of Calpain-1 cleaved \u03b1-Synuclein quantified in serum is upregulated in patients with Parkinson\u2019s disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Signe","family":"Holm Nielsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilie","family":"M\u00f8ller Hausgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meryem","family":"Benmarce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"92726_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3233\/JPD-202346","volume":"11","author":"RJ Port","year":"2021","unstructured":"Port, R. J. et al. People with Parkinson\u2019s disease: what symptoms do they most want to improve and how does this change with disease duration?? J. Parkinsons Dis. 11, 715\u2013724 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"92726_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"E Ray Dorsey","year":"2018","unstructured":"Ray Dorsey, E. et al. Global, regional, and National burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 17, 939 (2018).","journal-title":"Lancet Neurol."},{"key":"92726_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/ejn.14094","volume":"49","author":"JC Greenland","year":"2019","unstructured":"Greenland, J. C., Williams-Gray, C. H. & Barker, R. A. The clinical heterogeneity of Parkinson\u2019s disease and its therapeutic implications. Eur. J. Neurosci. 49, 328\u2013338 (2019).","journal-title":"Eur. J. Neurosci."},{"key":"92726_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet (London England). 386, 896\u2013912 (2015).","journal-title":"Lancet (London England)"},{"key":"92726_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2125.2012.04192.x","volume":"74","author":"TC Vu","year":"2012","unstructured":"Vu, T. C., Nutt, J. G. & Holford, N. H. G. Progression of motor and nonmotor features of Parkinson\u2019s disease and their response to treatment. Br. J. Clin. Pharmacol. 74, 267\u2013283 (2012).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"92726_CR6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","volume":"89","author":"M Lawton","year":"2018","unstructured":"Lawton, M. et al. Developing and validating Parkinson\u2019s disease subtypes and their motor and cognitive progression. J. Neurol. Neurosurg. Psychiatry. 89, 1279\u20131287 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"92726_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0329-1","volume":"14","author":"RM Meade","year":"2019","unstructured":"Meade, R. M., Fairlie, D. P. & Mason, J. M. Alpha-synuclein structure and Parkinson\u2019s disease. Mol. Neurodegener. 14, 1\u201314 (2019).","journal-title":"Mol. Neurodegener"},{"key":"92726_CR8","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1073\/pnas.0406976102","volume":"102","author":"W Li","year":"2005","unstructured":"Li, W. et al. Aggregation promoting C-terminal Truncation of \u03b1-synuclein is a normal cellular process and is enhanced by the Familial Parkinson\u2019s disease-linked mutations. Proc. Natl. Acad. Sci. U S A. 102, 2162\u20132167 (2005).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"92726_CR9","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.1021\/bi047846q","volume":"44","author":"AJ Mishizen-Eberz","year":"2005","unstructured":"Mishizen-Eberz, A. J. et al. L. D. Cleavage of \u03b1-Synuclein by Calpain: potential role in degradation of fibrillized and nitrated species of \u03b1-Synuclein. Biochemistry 44, 7818\u20137829 (2005).","journal-title":"Biochemistry"},{"key":"92726_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/hmg\/ddl030","volume":"15","author":"I Mizuta","year":"2006","unstructured":"Mizuta, I. et al. F. J. Multiple candidate gene analysis identifies \u03b1-synuclein as a susceptibility gene for sporadic Parkinson\u2019s disease. Hum. Mol. Genet. 15, 1151\u20131158 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"92726_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13547500902777608","volume":"14","author":"M Karsdal","year":"2009","unstructured":"Karsdal, M. et al. Biochemical markers and the FDA critical path: how biomarkers May contribute to the Understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14, 181\u2013202 (2009).","journal-title":"Biomarkers"},{"key":"92726_CR12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2353\/ajpath.2007.061232","volume":"170","author":"BM Dufty","year":"2007","unstructured":"Dufty, B. M. et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170, 1725\u20131738 (2007).","journal-title":"Am. J. Pathol."},{"key":"92726_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1749-6632.1994.tb44402.x","volume":"747","author":"RA Nixon","year":"1994","unstructured":"Nixon, R. A. et al. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer\u2019s disease. Ann. N Y Acad. Sci. 747, 77\u201391 (1994).","journal-title":"Ann. N Y Acad. Sci."},{"key":"92726_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1471-4159.2003.01878.x","volume":"86","author":"AJ Mishizen-Eberz","year":"2003","unstructured":"Mishizen-Eberz, A. J. et al. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by Calpain I in vitro. J. Neurochem. 86, 836\u2013847 (2003).","journal-title":"J. Neurochem"},{"key":"92726_CR15","doi-asserted-by":"publisher","first-page":"22670","DOI":"10.1074\/jbc.M501508200","volume":"280","author":"CW Liu","year":"2005","unstructured":"Liu, C. W. et al. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280, 22670\u201322678 (2005).","journal-title":"J. Biol. Chem."},{"key":"92726_CR16","doi-asserted-by":"publisher","first-page":"8530","DOI":"10.1021\/bi027363r","volume":"42","author":"IVJ Murray","year":"2003","unstructured":"Murray, I. V. J. et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 8530\u20138540 (2003).","journal-title":"Biochemistry"},{"key":"92726_CR17","doi-asserted-by":"publisher","unstructured":"Atik, A., Stewart, T. & Zhang, J. Alpha-Synuclein as a biomarker for Parkinson\u2019s disease. https:\/\/doi.org\/10.1111\/bpa.12370","DOI":"10.1111\/bpa.12370"},{"key":"92726_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF01551818","volume":"3","author":"ML Gefter","year":"1977","unstructured":"Gefter, M. L., Margulies, D. H. & Scharff, M. D. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell. Genet. 3, 231\u2013236 (1977).","journal-title":"Somatic Cell. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92726-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92726-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92726-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:23:30Z","timestamp":1744176210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92726-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92726"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92726-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SHN, CMH, MB, MAK and KH are full-time employees at Nordic Bioscience A\/S. Nordic Bioscienceis a privately-owned, small\u2013medium-size enterprise (SME) partly focused on developing biomarkers. None of the authors received fees, bonuses, or other benefits for the work described in the manuscript. SHN, MAK, and KH hold stocks in Nordic Bioscience A\/S.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12081"}}